AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
AbbVie has tacked down its first regulatory approval for risankizumab as it begins what it hopes is a global rollout for the psoriasis drug in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
